Kestra Private Wealth Services LLC Purchases 883 Shares of McKesson Corporation $MCK

Kestra Private Wealth Services LLC increased its position in McKesson Corporation (NYSE:MCK) by 37.9% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,213 shares of the company’s stock after acquiring an additional 883 shares during the period. Kestra Private Wealth Services LLC’s holdings in McKesson were worth $2,636,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. GGM Financials LLC purchased a new position in McKesson in the 3rd quarter worth about $25,000. State of Wyoming purchased a new stake in shares of McKesson during the 2nd quarter valued at about $29,000. Hopwood Financial Services Inc. purchased a new stake in shares of McKesson during the 3rd quarter valued at about $31,000. Vermillion & White Wealth Management Group LLC bought a new stake in shares of McKesson in the third quarter worth approximately $33,000. Finally, Board of the Pension Protection Fund bought a new stake in shares of McKesson in the fourth quarter worth approximately $33,000. 85.07% of the stock is owned by institutional investors.

Insider Buying and Selling

In other McKesson news, EVP Michele Lau sold 2,725 shares of the company’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $990.00, for a total value of $2,697,750.00. Following the completion of the sale, the executive vice president owned 3,247 shares in the company, valued at $3,214,530. This represents a 45.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Leann B. Smith sold 190 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $945.00, for a total value of $179,550.00. Following the completion of the transaction, the executive vice president directly owned 2,989 shares in the company, valued at $2,824,605. This trade represents a 5.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 3,592 shares of company stock valued at $3,518,555 in the last 90 days. 0.08% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on MCK shares. Wall Street Zen downgraded shares of McKesson from a “buy” rating to a “hold” rating in a research report on Saturday, April 11th. Robert W. Baird set a $968.00 target price on shares of McKesson in a research note on Wednesday, January 14th. Raymond James Financial set a $970.00 price target on McKesson in a report on Thursday, March 5th. JPMorgan Chase & Co. raised their price target on McKesson from $983.00 to $1,107.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 10th. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $966.00 price objective on shares of McKesson in a report on Thursday, January 29th. Fourteen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $972.27.

McKesson News Roundup

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson sold its stake in Medical‑Surgical Solutions, a move that could unlock cash and simplify the company’s portfolio — potentially supporting buybacks or redeployment of capital. McKesson sells stake in Medical-Surgical Solutions
• Positive Sentiment: McKesson Canada secured national distribution for naturemary, expanding reach into thousands of pharmacies — a small but constructive revenue/market-access win in consumer and retail channels. naturemary Secures National Distribution with McKesson Canada, Unlocking Access to Thousands of Pharmacies
• Positive Sentiment: McKesson put a new $5.0 billion senior unsecured revolving credit facility in place, strengthening liquidity and debt flexibility ahead of potential strategic investments or cash-return programs. McKesson Secures New $5 Billion Revolving Credit Facility
• Neutral Sentiment: Analysts are re‑weighing McKesson’s valuation relative to its biosimilars/co‑manufacturing optionality; fair value estimates moved only marginally, but individual price targets diverge — highlights evolving thesis but no consensus catalyst yet. How The Narrative On McKesson (MCK) Is Shifting Around Biosimilars And Valuation Premium
• Neutral Sentiment: Investor pieces pitching McKesson as a way to play GLP‑1 channel growth highlight upside scenarios but are speculative and unlikely to move fundamentals immediately. GLP-1 trade? McKesson is your stock, this investor says
• Neutral Sentiment: Reports that lawmakers have been increasing holdings in McKesson attracted press attention — notable for optics but not a direct operational driver. Lawmakers increase stakes in McKesson, Boeing, Alphabet amid scrutiny
• Negative Sentiment: Market coverage noted McKesson fell more steeply than the broader market today, reflecting investor selling pressure and concerns over the stock’s premium to historical averages. McKesson (MCK) Falls More Steeply Than Broader Market: What Investors Need to Know
• Negative Sentiment: Competitor coverage (William Blair initiating Cardinal Health at Outperform) highlights investor appetite for distributor exposure elsewhere, which could pressure McKesson’s multiple if flows shift to peers. William Blair Initiates Cardinal Health at Outperform: Is the Pharma Distributor a Stealth Compounder?

McKesson Trading Down 1.4%

MCK opened at $823.68 on Thursday. The company’s 50 day moving average is $897.30 and its 200 day moving average is $859.47. The company has a market cap of $100.89 billion, a price-to-earnings ratio of 23.69, a PEG ratio of 1.20 and a beta of 0.42. McKesson Corporation has a 12-month low of $637.00 and a 12-month high of $999.00.

McKesson (NYSE:MCK) last announced its earnings results on Wednesday, February 4th. The company reported $9.34 EPS for the quarter, beating analysts’ consensus estimates of $9.19 by $0.15. The business had revenue of $106.16 billion during the quarter, compared to analysts’ expectations of $105.98 billion. McKesson had a net margin of 1.09% and a negative return on equity of 338.97%. The firm’s revenue was up 11.4% on a year-over-year basis. During the same period in the prior year, the company earned $8.03 earnings per share. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. As a group, analysts predict that McKesson Corporation will post 39.02 EPS for the current fiscal year.

McKesson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 1st. Investors of record on Monday, June 1st will be issued a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Monday, June 1st. McKesson’s dividend payout ratio (DPR) is currently 9.43%.

McKesson Company Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.